Canntab Therapeutics Limited
OTC: CTABF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Richard C. Goldstein
- Headquarters
- Markham, Canada
- IPO year
- 2017
- Market cap
- $3.9K
- Website
- https://canntab.ca
Loading CTABF…
Loading profile data…Frequently asked questions about CTABF
What does Canntab Therapeutics Limited (CTABF) do?
Canntab Therapeutics Limited is a Canadian phytopharmaceutical firm dedicated to pioneering the research and development of sophisticated, pharmaceutical-grade cannabinoid preparations. The company manufactures various oral cannabis medications, including extended-release cannabinoid pills and pellets, rapidly acting cannabidiol formulations, mu...
Where does CTABF trade?
Canntab Therapeutics Limited (CTABF) trades on the Other OTC.
What sector is CTABF in?
Canntab Therapeutics Limited (CTABF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Canntab Therapeutics Limited?
Richard C. Goldstein is the chief executive officer of Canntab Therapeutics Limited (CTABF).
Where is Canntab Therapeutics Limited headquartered?
Canntab Therapeutics Limited is headquartered in Canada.
Does CTABF pay a dividend?
Canntab Therapeutics Limited (CTABF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CTABF go public?
Canntab Therapeutics Limited (CTABF) completed its initial public offering in 2017.